Thyrocare Technologies Q3 FY26 – Healthy Growth with Improving Profitability

Thyrocare delivered a solid performance in the December 2025 quarter, supported by steady growth in diagnostic volumes and improved operating efficiency, leading to strong expansion in earnings. Sales: ↑ 18% YoY to ₹196 crore (vs ₹166 crore in Dec 2024) EBIDT: ↑ 39% YoY to ₹57.8 crore (vs ₹41.6 crore) Net Profit: ↑ 75% YoY to ₹28.0 crore (vs ₹19.0 crore) EPS: ↑ 52% YoY to ₹1.82 (vs ₹1.20) At a price of ₹459, market cap ₹7,305 crore, and PE 51.4, Thyrocare reflects a premium for its strong brand and scalable diagnostic platform. The faster growth in profits compared to revenue highlights operating leverage and margin improvement, positioning the company well for sustained growth in India’s expanding preventive healthcare market.